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Objective: Most commercially available fibrin sealants contain aprotinin in
doses of 1500 kallikrein inactivator units per milliliter. They are used in
many operative disciplines. An elevated risk of hypersensitivity reactions
exists at reexposure to aprotinin. Our aim was to examine the immunogenic
potency of aprotinin as a fibrin sealant content. Methods: We investigated
49 children with operatively treated congenital heart disease. All patients
received aprotinin only topically as contained in fibrin sealant. Serum
samples were drawn preoperatively, 1 week, 2 weeks, 6 weeks, and approx-
imately 1 year after operation. They were analyzed for aprotinin-specific
immunoglobulin G antibodies with a standard enzyme-linked immunosor-
bent assay and a fluorescence enzyme immunoassay for aprotinin-specific
immunoglobulin E antibodies. Results: At 1 week, 2 weeks, 6 weeks, and 1
year, we found prevalences of 8% (2 of 26), 8% (2 of 24), 6% (3 of 49), and
0% for aprotinin-specific Immunoglobulin E, and for aprotinin-specific
immunoglobulin G 8% (2 of 26), 17% (4 of 24), 39% (19 of 49), and 12% (5
of 41). The doses of aprotinin given did not differ significantly in antibody-
negative and antibody-positive patients; no significant factors could predict
the immune response. Conclusions: Our findings show the existence of a
subgroup of patients who had aprotinin-specific antibodies develop after
topical aprotinin application. Any use of aprotinin must be carefully
documented. If aprotinin use is planned in patients who previously
underwent a surgical procedure, preexposure to aprotinin in any form must
be sought to avoid unexpected anaphylactic reactions. The necessity itself
and alternatives for aprotinin as a stabilizing agent in fibrin sealants merit
consideration. (J Thorac Cardiovasc Surg 1998;115:883-9)
Aprotinin is a polyvalent proteinase inhibitor frombovine organs. Since the 1980s, it has been used
in high doses of several million kallikrein inactivator
units (KIU) for its beneficial effect on perioperative
blood loss and transfusion requirements in cardiac
operations.1, 2 It is also used in small concentrations
of about 1500 KIU/ml in commercially available
fibrin sealants because it significantly extends the
resorption of the fibrin clot in the physiologic envi-
ronment.3 These biologic sealants are increasingly
used in many surgical disciplines.4, 5 In Europe and
several Asian countries these products have been
commercially available since the early 1980s. The
U. S. Food and Drug Administration is presently
considering approval of a commercially available
fibrin sealant in the United States.
As a foreign protein composed of 58 amino acid
residues with a molecular weight of 6512 daltons,
aprotinin is capable of triggering hypersensitivity
reactions, particularly after systemic reexposure.6
The frequency of severe allergic and pseudoallergic
reactions after systemic reexposure is estimated to
be between 0.1% and 5.8%.7, 8 There are also re-
ports of fatal adverse reactions.9, 10
Antigen-specific antibodies play a decisive role in
adverse reactions of sensitized patients at reexpo-
sure to antigens: antibodies of the immunoglobulin
(Ig) E class are responsible for “true” anaphylactic
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reactions11; antibodies of the IgG class may trigger
anaphylactoid reactions through the involvement of
the complement system.12, 13 Such anaphylactoid
reactions cannot be clinically distinguished from
true anaphylactic reactions.
The incidence of specific IgE antibodies within 8
weeks after a course of several infusions of aprotinin
for acute pancreatitis was estimated to be about
32% (95% confidence interval: 19% to 48%) (14 of
44) of patients.14 The prevalence of aprotinin-spe-
cific IgG antibodies was estimated to be about 40%
to 50% of adult patients exposed to one first sys-
temic high dose of aprotinin during cardiac opera-
tion half a year earlier.15, 16
Recent articles discussed the immunogenic effect
of low aprotinin doses such as those contained in
commercially available fibrin sealants.10, 17 There
are two case reports of severe unexpected reactions
accompanied by circulatory collapse in which the
aprotinin component of fibrin sealant could be
identified as the causative agent.18, 19
The immunogenic effect of aprotinin contained in
commercially available fibrin sealants has not yet
been examined in a clinical study. No data are
available for adults or children about the prevalence
and time course of aprotinin-specific antibodies
after a first and single exposure to commercially
available fibrin sealant.
Patients and methods
Patients Forty-nine children (29 male, 20 female) un-
dergoing cardiac operations between April 1995 and
November 1995 and receiving fibrin sealant for the first
time (median dose: 2.0 ml, 7090 KIU/m2 body surface
area) were the subjects of the study. This represents 38%
of all children (49 of 130) operated in our division during
that time frame. The median age of the patients was 15.2
months (50% range: 4 months to 311⁄12 years). The correc-
tive operations comprised the whole spectrum of congen-
ital heart disease from direct atrial septal defect closure to
complex reconstructions and definitive surgery in univen-
tricular hearts.
Table I shows the distribution of the patients according
to age and lesions.
Forty-three patients (88%) were operated on with the
use of cardiopulmonary bypass, 17 of them with deep
hypothermic circulatory arrest (17 of 43, 40%); there were
six closed procedures, such as palliative shunts or coarc-
tectomy.
Sixteen of the 49 children underwent cardiac reopera-
tions. Most of the primary operations consisted of valvot-
omy for critical aortic stenosis or shunt procedures in
cyanotic newborns with complex disease. Neither applica-
tion of fibrin sealant nor infusion of aprotinin had been
documented for these primary operations.
Methods All parents were informed about the aim of
the study and consent was given in writing. The decision to
use fibrin sealant was only made intraoperatively because
of operative necessity. All patients received 0.7 to 12 ml of
a commercially available fibrin sealant (Tissucol Duo S,
Immuno, Vienna, Austria), consisting of two components:
a plasma fraction (containing 70 to 110 mg fibrinogen, 2 to
9 mg plasma fibronectin, 10 to 50 U coagulation factor
VIII, 0.02 to 0.08 mg plasminogen (all human), and 3000
KIU (i.e., 0.42 mg) bovine aprotinin per 1 ml and a
thrombin fraction (containing 500 U human thrombin and
5.88 mg calcium chloride per 1 ml).
In all patients, aprotinin was applied only topically in
the mediastinum, but not systemically. Children with
previous contact with aprotinin, as ascertained from their
history, documentation in the chart, and a preoperative
serum sample positive for aprotinin-specific antibodies,
were excluded from the study. To avoid allergic reactions
or immunologic interference, we purposely did not per-
form skin testing.
A complete history of allergies was taken, including the
patient’s own and their family’s history of atopic diathesis.
The questionnaire also covered the patient’s complete
medical history emphasizing immunologically important
factors such as susceptibility to infections (children having
had two or more infections during the 3 months preceding
the operation were considered as being susceptible to
infections), the patient’s history of long-term drug ther-
apy, and vaccinations.
Serum samples were obtained preoperatively, 1 week, 2
weeks, 6 weeks, and approximately 1 year postoperatively.
They were centrifuged for 15 minutes at 10° C at 1200 G,
and stored at –20° C until the in vitro tests were per-
formed.
One week after the operation we obtained the sera of
26 patients and after 2 weeks those of 24 patients. At a
routine examination 6 weeks postoperatively we obtained
the sera of all 49 patients. After 1 year, we obtained the
sera of 41 children: two others had died and six were lost
to follow-up or refused further blood sampling. Preoper-
ative sera had been stored from all 49 patients. No child
underwent reoperations during the observation time.
Analyses. Analyses included assays for the detection of
total serum IgE and IgG levels and aprotinin-specific IgG
and IgE antibodies with the techniques described below:
UniCAP System. Total serum IgE and aprotinin-specific
IgE antibodies were quantified with the automatic Phar-
macia UniCAP device (Pharmacia & Upjohn, Uppsala,
Sweden) using a fluorescence enzyme immunoassay
(FEIA). Quantitative expression of results was obtained
by using standard reagents calibrated against World
Table I. Distribution of patients according to age
and lesions
Age (mo)
0 # 1 1 # 12 .12 Total
Acyanotic n
(% of total)
3 (6.1) 8 (16.3) 19 (38.8) 30 (61.2)
Cyanotic n
(% of total)
4 (8.2) 7 (14.3) 8 (16.3) 19 (38.8)
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Health Organization reference preparations for human
IgE (75/502).
Total serum IgE levels greater than 120 kilo-Units per
liter were considered elevated.
Concentrations of aprotinin-specific IgE are expressed
in kilo-Units of allergen-specific IgE per liter (kUA/L) and
evaluated according to the conventional radioallergosor-
bent classes: values of 0.35 kUA/L and greater represent a
progressive increase in the relative concentration of aller-
gen-specific antibodies (Table II). Values less than 0.35
kUA/L represent absent or undetectable levels of allergen-
specific antibodies.
Enzyme-linked immunosorbent assay Ninety-six–Well-
Immuno-Plates (Maxisorp, Nunc GmbH, Wiesbaden,
Germany) were coated with an antigen solution contain-
ing 5 mg aprotinin (36 KIU Trasylol, Bayer, Leverkusen,
Germany) per milliliter Tris-buffered saline solution (Sig-
ma Chemical Company, St. Louis, Mo.). The plates were
incubated overnight at 4° C and washed five times with
300 ml TTBS (Tris-buffered saline solution plus 0.05%
Tween 20; Merck-Schuchardt, Hohenbrunn, Germany)
per well. This washing procedure was repeated after each
subsequent step. The wells were blocked with 300 ml
blocking reagent (Blocking reagent for enzyme-linked
immunosorbent assay [ELISA], Boehringer Mannheim,
Germany) per well and incubated for 60 minutes at room
temperature. Then 100 ml samples or control serum
diluted 1:100 in 0.9% NaCl were added per well. Serum
with known concentrations of aprotinin-specific antibod-
ies (IgG: 114 mg/L, RAST-FEIA), obtained from a pa-
tient who had had an anaphylactic reaction to aprotinin as
described elsewhere,20 served as a positive reference. Six
dilutions from 1:25 to 1:1600 were used to establish the
reference curve. Negative controls were obtained from a
pool of 20 donors without prior contact with aprotinin.
NaCl, 0.9%, was used as a blank. After 120 minutes of
incubation at room temperature, 100 ml alkaline phos-
phatase–conjugated goat anti-human g-chain specific IgG
(Sigma) were added per well. The antibody-enzyme-
conjugate was used in a dilution of 1:10,000 in 1% bovine
serum albumin (Sigma) and TTBS. The plates were
incubated again for 90 minutes at room temperature,
followed by the addition of 100 ml p-nitrophenyl phos-
phate solution (Sigma Fast pNPP Tablets, soluble alkaline
phosphatase substrate, Sigma) per well, and the absor-
bance was read at 405 nm using an ELISA-Reader
(Dynatech Lab, Denkendorf, Germany). Because the
semilogarithmic reference curve was linear for aprotinin-
specific IgG concentrations of 10 to 400 mg/L and the
mean plus three standard deviations of 20 negative con-
trols was less than 10 mg/L, serum concentrations higher
than 10 mg/L of aprotinin-specific IgG were considered
positive for aprotinin-specific IgG.
Western blotting. A solution of reduced aprotinin (Tra-
sylol, heated for 5 minutes at 95° C with addition of 1
grain of dithiothreitol) was concentrated in a polyacryl-
amide gel by means of electrophoresis and subsequently
transferred to a nitrocellulose membrane (Probind 45,
Pharmacia, Uppsala, Sweden) with an electroblotting
technique with the appropriate material (Mini-Protean II
Multiscreen, Bio-Rad, Munich, Germany, and Multiphor
II, Pharmacia-LKB, Bromma, Sweden). These mem-
branes were then incubated with the test specimen and the
control specimen in the appropriate test system (Mini-
Protean II Multiscreen). Aprotinin-specific IgG antibod-
ies contained in the 1:100 in TBS (Loewe Biochemica,
Otterfing, Germany) diluted sera bind to the nitrocellu-
lose, on which they are visualized by an enzymatic staining
reaction (5-bromo-4-chloro-3-indolyl phosphate/nitro-
blue tetrazolium, Sigma Fast BCIP/NBT Tablets, Sigma)
after incubation with a secondary enzyme-labeled anti-
human IgG-antibody diluted 1:30,000 in TBS (goat anti-
human IgG-AP, g-chain specific, Sigma). The test bonds
were compared with those of the control sera and divided
by sight into the categories “positive,” “questionably pos-
itive,” and “negative.”
Nephelometry. The evaluation of total serum IgG con-
centrations was performed in the clinic’s routine labora-
tory with a Behring Nephelometer (Behringwerke AG,
Marburg, Germany) according to the operating instruc-
tions and with the appropriate reagents purchased from
Behring.
Statistical analysis. Values that are not normally dis-
tributed are shown as medians with 50% range; normally
distributed values are portrayed as means with standard
deviation. Percentages are presented with 95% confidence
intervals for the probability based on the binomial distri-
bution in brackets. The influence of antigen dose, age,
body surface area, and preexisting allergies on the preva-
lence of antibody formation was tested with a multiple
logistic regression analysis using the statistical package
JMP.
Results
Aprotinin-specific antibodies. The number of pa-
tients positive for aprotinin-specific antibodies at
the respective dates of blood-sampling (i.e., preva-
lence) is shown in Fig. 1.
The incidence of aprotinin-specific IgE antibodies
within the observation time was 14.3% (5% to 24%),
Table II. RAST/FEIA classes
RAST/FEIA classes
0 I II III IV V VI
Aprotinin-specific IgE (kUA/L) ,0.35 $0.35 $0.7 $3.5 $17.5 $50 $100
Antibody level Absent or
undetectable
Low Moderate High Very high Very high Very high
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that is, 7 of 49 children. The course of aprotinin-
specific IgE levels in the seven IgE-positive patients
is shown in Table III. The children who were
positive for aprotinin-specific IgG at 1 and 2 weeks
remained positive through at least 6 weeks. Four of
the five children who were positive at 1 year had
already been positive at 6 weeks. Six children were
positive for both IgG and IgE; this represents 32%
(13% to 57%) (i.e., 6 of the 19 IgG-positive chil-
dren).
Total antibody concentrations. Six children pre-
sented with elevated total serum IgE levels. Two of
these presented with both aprotinin-specific IgE and
IgG. Measurements of total serum IgG were all
within the normal range for the respective age
except for four children with too-low-for-age total
IgG concentrations. Only one of them presented
with aprotinin-specific IgG.
Western blot versus ELISA. When we used the
Western blot technique for the 49 sera sampled 6
weeks postoperatively, we detected 12 positive
(24%), 13 questionably positive (27%), and 24
(49%) negative sera. The results of ELISA and
Western blotting were comparable for very high
concentrations and for negative sera. Low concen-
trations measured by ELISA mostly produced a
“questionably positive” with the Western blot tech-
nique.
Clinical and pharmacologic influences. In Table
IV we show antibody formation together with the
factors aprotinin dosage, age, and body surface
area.
Fig. 1. Prevalence of aprotinin-specific antibodies.
Table III. Course of aprotinin-specific IgE levels in the seven IgE-positive patients
Patients Age (mo)
Fibrin
sealant
(ml)
Aprotinin
dose
(KIU/m2 BSA)
Aprotinin-specific IgE levels (kUA/L, RAST-class)
Preoperatively
Postoperatively at
1 wk 2 wk 6 wk 1 yr
1 4 2 9375 ,0.35 ,0.35 ,0.35 0.63 (I) ,0.35
2 8 4 17,647 ,0.35 ,0.35 ,0.35 0.38 (I) ,0.35
3 44 3 6818 ,0.35 ,0.35 0.72 (II) ,0.35 ,0.35
4 49 3 7031 ,0.35 0.47 (I) No serum ,0.35 ,0.35
5 49 6 14,031 ,0.35 6.08 (III) No serum ,0.35 ,0.35
6 146 2 6430 ,0.35 No serum No serum 2.6 (II) ,0.35
7 47 5 11,719 ,0.35 No serum 0.41 (I) ,0.35 ,0.35
KIU/m2 BSA, Kallikrein inhibiting units per square meter body surface area; BSA, body surface area.
The Journal of Thoracic and
Cardiovascular Surgery
April 1998
8 8 6 Scheule et al.
Formation of aprotinin-specific antibodies was
independent of sex, atopic diathesis, susceptibility to
infections, and postoperative long-term medication.
Comments
In this prospective study we could clearly docu-
ment that there is a systemic immune response to
small topical doses of aprotinin. Our data show an
initial rise of the frequency of antibody detection
within at least 6 weeks, followed by a distinct decline
after 1 year.
As has already been shown for high-dose systemic
application, small topical aprotinin doses may also
induce an aprotinin-specific IgE response. Yanagi-
hara and Shida14 examined patients who received a
course of several high-dose infusions of aprotinin
for acute pancreatitis. They found aprotinin-specific
IgE in 24% (11% to 39%) at 2 weeks (9 of 37) and
30% (12% to 54%) at 8 weeks (6 of 20).
The prevalence of aprotinin-specific IgG response
after topical application is comparable to the prev-
alence reported after high-dose systemic aprotinin
administration. Ruskowski and colleagues15 for a
group of more than 250 patients with first time
systemic high-dose aprotinin application reported a
prevalence of aprotinin-specific IgG antibodies of
16.7% after 4 to 6 weeks and of 46.4% after 6 to 7
months. In a similar study Pfannschmidt and col-
leagues16 reported 3.6% aprotinin-specific IgG-pos-
itive after 3 to 4 weeks (2 of 56) and 46.6% after 6
months (26 of 56). In contrast to our findings, both
studies revealed no aprotinin-specific IgE. This
might be due to procedural differences: they used
immunoblotting and ELISA and we used FEIA.
Another reason may be that they examined adult
patients.
IgE antibodies sensitize mast cells and basophil
granulocytes by binding to specific receptors on
their surface. When an antigen cross-links two sur-
face-bound IgEs, these cells release mediators that
cause the clinical symptoms of anaphylaxis.11 As for
aprotinin, there are two documented cases of ana-
phylactic reactions with preformed aprotinin-spe-
cific IgE antibodies.20, 21
The role of antigen-specific IgG for anaphylactic
and anaphylactoid reactions is the subject of contro-
versy. Its significance may depend on the distribu-
tion of its subclasses13 or the ratio of IgE/IgG.22 It
has been shown that specific IgG subclasses may
also trigger severe or even fatal reactions.13, 23 One
explanation may be the so-called immune complex
anaphylaxis in which anaphylactic mediators are
released by activation of the complement system
through the classical and/or the alternate pathway.12
Another explanation may be the “homocytotropic
activity” of the IgG4 subclass (i.e., its capability of
binding to mast cells and thereby acting as an
anaphylactic antibody).22, 23
In the literature from 1963 to 1997 we found 95
cases* of adult patients with anaphylactic or anaphy-
* Thirty-eight cases are presented in references 6, 8-10, 14, 17-21;
the remainder cannot be cited for reasons of space because
these 57 cases are reported in 33 other publications.
Table IV. Clinical and biologic data
n
Whole
group
as-IgE
positive
as-IgE
negative
as-IgG
positive
as-IgG
negative
49 7 42 19 30
Fibrin sealant
Median (ml) 2 3 2 3 2
50% range 1-3 3-4.5 1-2 2-4.5 1-2
Aprotinin dosage
Median (KIU/m2 BSA) 7090 9375 6410 8900 6440
50% range 4290-12,500 6930-12,900 3500-12,260 5340-13,850 4290-10,350
Significance ns ns
Age
Median (mo) 15.2 46.6 14.0 44.0 8.0
50% range 4-49 26-49 4-44 10-62 3-30
Significance ns ns
Body surface area (BSA)
Median (m2) 0.41 0.64 0.4 0.58 0.35
50% range 0.32-0.64 0.49-0.65 0.31-0.62 0.39-0.68 0.27-0.53
Significance ns ns
as, Aprotinin-specific; ns, not significant.
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lactoid reactions to aprotinin. Preexposure to apro-
tinin was documented in 63 of these cases. From the
clinical data given it was possible to infer the time
interval between preexposure and reexposure in 40
cases: the large majority of 27 occurred within 1
week to 3 months, only 13 occurred within a long
period of 4 months to 4 years after preexposure. The
peak of specific IgE and IgG antibody detection in
our patients is in accordance with the distribution of
reports over time observed in the literature.
The presence of allergen-specific antibodies does
not necessarily lead to anaphylactic reactions24; they
represent a risk factor for allergic reactions. In the
literature we found reports of 27 patients with
anaphylactic reactions to aprotinin whose sera had
been examined for aprotinin-specific IgE, 17 of
them were positive postreactively.9, 14, 15, 17, 18, 20, 21
Therefore especially in patients with a positive
aprotinin-specific antibody screening test the indica-
tion for fibrin sealant containing aprotinin or sys-
temic aprotinin should be reconsidered. If the indi-
cation is mandatory, we recommend precautionary
measures such as pulse oximetry, monitoring of the
arterial blood pressure, an intravenous line, and an
antiallergic pretreatment at reexposure.
When we looked for predictive parameters for the
aptitude to form aprotinin-specific antibodies, our
data did not show any. This negative result can be
attributed to the number of patients being too small
for reliable epidemiologic calculations. Large clini-
cal studies on anesthetic drugs revealed atopy and
female gender as risk factors for IgE-mediated
reactions.25
The benefit of fibrin sealant for local hemostasis
has been shown in extensive clinical studies.26, 27
Although aprotinin extends significantly the time of
resorption of the fibrin clot from 3 to more than 28
days, it has not yet been investigated in a clinical
study if the aprotinin component is indispensable
for that indication. If a stable fibrin clot is necessary
for more than a few days, possible alternatives such
as e-aminocaproic acid, which stabilizes the clot for
7 days,3 or an augmentation of the factor XIII
component should be considered.
Contrary to Pfannschmidt and colleagues’ find-
ings16 that the Western blotting method was more
sensitive for IgG detection than ELISA, we had
clearer results using ELISA. This may be due to
procedural differences.
In the absence of published data about the close
time course of antibody formation, we chose four
fixed intervals for blood sampling after a single dose
of aprotinin, considering the organizational practi-
cality and the stress for the children and for their
parents. Therefore the frequency of antibody forma-
tion in the period between 6 weeks and 1 year after
exposure remains uncertain.
A limitation of our study is the small number of
samples after 1 and 2 weeks because many children
had been transferred early to other hospitals. After
6 weeks, all children were reexamined in the division
of pediatric cardiology at our hospital. The parents’
compliance after 1 year was excellent. All parents
were informed in writing about the results and
implications.
Conclusions
The existence of patients forming aprotinin-spe-
cific antibodies caused by a previous topical aproti-
nin application has been proven. There was an
increase of aprotinin-specific antibody–positive pa-
tients during the first 6 weeks after application of
fibrin sealant. Most anaphylactic and anaphylactoid
reactions to aprotinin reported in the literature
occurred in a comparable time lapse between pre-
exposure and reexposure.
As a practical consequence, any use of aprotinin,
even in fibrin sealant, must be carefully docu-
mented. If aprotinin use is planned in a patient who
has undergone a previous operative procedure, es-
pecially during the past several months, previous
exposure to aprotinin in any form must be sought.
For patients with recent aprotinin exposure, the
indication for aprotinin readministration should be
carefully reconsidered. If the expected benefit of
fibrin sealant application in these patients outweighs
the possible risk of anaphylaxis, we recommend
stringent precautionary measures at reexposure.
The usefulness of aprotinin-specific antibody
screening remains the subject of further research.
The need for aprotinin in fibrin sealants and the use
of possible alternatives as stabilizing agents merits
consideration.
We express our gratitude to R. Storf, BSc, E. Steil, MD,
and I. Besenthal, MD, PhD, for their help.
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